Patient appointments
MASH is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. The degree of fibrosis changes treatment decisions. Simple fatty liver on an ultrasound does not prove MASH or eligibility for Rezdiffra or Wegovy’s MASH indication.
An appointment does not confirm access to a particular medicine, procedure or specialist. Ask the team about the care and coverage you need.
MASH is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. The degree of fibrosis changes treatment decisions. Simple fatty liver on an ultrasound does not prove MASH or eligibility for Rezdiffra or Wegovy’s MASH indication.
Adults with suspected liver fat or fibrosis need assessment of cause, metabolic risk, and severity. The labeled MASH treatments apply to adults with noncirrhotic MASH and F2–F3 fibrosis. Cirrhosis and other liver diseases need distinct care.
Review liver tests, imaging, noninvasive fibrosis assessments, alcohol, viral risks, medicines, and supplements. A clinician may coordinate hepatology and further testing; biopsy is not automatically required for every patient. Discuss nutrition, activity, diabetes and lipid care, and product-specific treatment when appropriate.
Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
Vomiting blood, new confusion or severe abdominal pain needs emergency department care now. Call 911 for confusion, severe breathing difficulty, fainting or unsafe travel. New jaundice or increasing abdominal swelling needs prompt medical assessment. Avoid unreviewed liver-detox supplements. A normal enzyme result is not permission to stop follow-up.
Follow liver and fibrosis assessment, metabolic goals, and medicine safety with the treating team. Rezdiffra and Wegovy combination decisions need individualized review. The trials and labels do not establish that a combination is appropriate for everyone.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
No. Insurance payment for the consultation does not guarantee payment for the medicine, testing or administration. Confirm the exact product and indication with the plan, including authorization, benefit rules and expected cost. Ask the clinic which services it provides and how each part of care will be billed.
Ask for separate current estimates for the evaluation, required tests, medicine, administration when relevant, and follow-up. Drug costs depend on product, dose, coverage, pharmacy, and savings eligibility. Self-pay still requires clinical review and monitoring. Confirm any manufacturer program’s current terms directly; a posted price does not guarantee your final cost.
Approval cannot be guaranteed. The plan reviews the exact treatment, indication and submitted records against its rules. Bring any denial or information request so the clinician can address the stated reason. Confirm the actual decision and remaining costs before relying on authorization as a treatment start.
Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
Choose a service and clinic in the Nao booking app. Confirm appointment availability and the care you need with the team.